Special: Crash Warning: Everything just changed



SRPT: Sarepta Therapeutics, Inc. is a Buy

The current rating for SRPT is 53, which is 6% above its historic median rating of 50. This indicates lower risk than normal.

The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.